The 'Andropause' / 'Low T' Construct
Manopause, the Abbott 'Is It Low T?' Campaign, and the FDA 2015 Class-Labeling Response
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- FDA 2015 class-wide labeling change restricted approved use to hypogonadism from specified medical conditions and required a cardiovascular warning
Reference only. Not medical advice.
What can go wrong
The marketing risk is medicalizing normal aging: men with normal testosterone or with treatable root causes (sleep apnea, depression, obesity) are placed on lifelong therapy, exposed to erythrocytosis, fertility loss, and monitoring costs. The FDA's 2015 action was an explicit regulatory rebuke of the off-label expansion the campaigns encouraged.
This is something to take to a clinician. The Atlas can tell you what is known about the 'andropause' / 'low t' construct in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
'Andropause,' 'manopause,' and 'Low T' are popular and marketing terms, not formal clinical diagnoses, that frame age-related testosterone change as a discrete deficiency disease analogous to menopause, an analogy clinicians reject because there is no abrupt, universal hormonal cessation in men. The construct was supercharged in the late 2000s and early 2010s by branded and unbranded 'disease-awareness' advertising, most prominently Abbott/AbbVie's 'Is It Low T?' campaign tied to the AndroGel franchise. US testosterone prescriptions roughly tripled in the early 2010s before cardiovascular-safety concerns prompted FDA action.
How a normal feature of aging was rebranded as a treatable deficiency disease.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
The construct works by anchoring on a real physiologic fact (testosterone does drift down with age) and stretching it into a disease with a high-prevalence, low-specificity symptom list. Because fatigue, weight gain, and low libido are nearly universal in middle age, almost anyone screens positive, which maximizes the funnel into paid evaluation and therapy.
What people get wrong
Often saidAndropause is the male menopause
ActuallyThere is no abrupt, universal cessation of gonadal function in men. The change is gradual, variable, and absent altogether in many healthy men. The menopause analogy is rhetorical, not physiological.
Often saidA positive 'Low T' quiz means you need testosterone
ActuallyThese checklists (e.g., ADAM) are sensitive but very nonspecific; most middle-aged men screen positive. They are lead-generation tools, not diagnostic tests.
Who profits, and who pushes back
FDA (2015 labeling action)
The benefit and safety of testosterone have not been established for age-related low testosterone; approved use is limited to hypogonadism due to certain medical conditions.
Endocrine Society
Recommends against routinely treating men with age-related decline absent unequivocally low levels and consistent symptoms.
How we got here
The word 'andropause' dates to mid-20th-century speculation about a male climacteric, but it gained commercial traction only once transdermal testosterone gels (AndroGel approved 2000) made convenient daily dosing possible. Through the 2000s, pharmaceutical disease-awareness advertising, symptom checklists like the ADAM questionnaire (sensitive but poorly specific), and a wave of dedicated 'men's clinics' converted a vague concept into a marketing engine. Abbott's 'Is It Low T?' campaign and the IsItLowT.com website urged men with fatigue, low libido, and weight gain to 'ask your doctor.' Prescriptions surged; a large share went to men who were never tested or whose levels were normal.
- 2000FDA approves AndroGel (transdermal testosterone gel)
- 2000sADAM questionnaire and 'men's health' clinics popularize symptom-based screening
- 2008-2012Abbott/AbbVie 'Is It Low T?' disease-awareness advertising; US testosterone prescribing roughly triples
- 2013-2014Observational studies (Vigen 2013 JAMA; Finkle 2014 PLoS ONE) raise cardiovascular signals; FDA convenes advisory committee
- March 2015FDA class-wide labeling action: approved use restricted to hypogonadism from specified medical conditions; mandatory CV warning
- 2018Multidistrict AndroGel litigation produces large jury verdicts over marketing/safety
- 2023TRAVERSE finds no MACE increase but signals (afib, fractures, AKI)
- Feb 2025FDA removes the boxed cardiovascular warning while keeping the indication restricted
Set against the alternatives
Unlike menopause, which is a defined, near-universal cessation of ovarian function with a clear hormonal endpoint, age-related testosterone decline in men is gradual, variable, and often modest, and many older men retain normal levels. The 'andropause/Low T' construct borrows the legitimacy of the menopause analogy while discarding its biological basis. Compared with the formal diagnosis of hypogonadism, which requires both consistent symptoms and repeatedly low morning testosterone, the marketing construct lowers the bar to a high-prevalence symptom checklist, converting normal aging into a treatable 'condition' and maximizing the pool of paying candidates.
| Marketing claim | What evidence supports | Where it overreaches | Honest framing |
|---|---|---|---|
| 'Low T is a disease like menopause' | T does decline gradually with age | No abrupt universal cessation in men | Slow drift, not an event |
| 'Fatigue/low libido = Low T' | Severe hypogonadism causes these | Symptoms nonspecific, common at midlife | Poor screening specificity |
| 'Most men over 40 need testing' | Guidelines test symptomatic men | Mass screening not recommended | Test with symptoms + low labs |
| 'TRT restores youth/vitality' | Helps confirmed hypogonadism | No proven anti-aging benefit | Replaces a deficiency only |
| 'It is safe, FDA-approved' | Approved for classical hypogonadism | 2015 label warned vs age-related use | Indication is narrow |
What we do not know
- Is there a clinically meaningful 'late-onset hypogonadism' syndrome distinct from comorbidity and obesity, or is most age-related symptomatology explained by other factors?
- What testosterone threshold, if any, best predicts benefit from treatment in older men with nonspecific symptoms?
- How much of symptomatic improvement on TRT in mid-range men is placebo versus true androgen effect?
- Did disease-awareness advertising change population testing/prescribing independent of clinical need, and what were the net outcomes?
- After the 2023 TRAVERSE data and 2025 label revisions, how should 'borderline' patients be counseled?
What could change
Reputational rehabilitation2023 TRAVERSE cardiovascular-safety data and 2025 FDA removal of the boxed warning soften prior cautionTelehealth funnelsOnline 'Low T' quizzes and direct-to-consumer panels revive the screening-to-prescription pipelineGLP-1 cross-marketingMen's-health brands bundling weight-loss drugs with hormone 'optimization' messagingGuideline tighteningSpecialty societies reiterating symptom-plus-confirmed-low-lab diagnosis against mass screeningDirect-to-consumer labsAt-home testosterone testing expanding the marketing surface for the construct
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about The 'Andropause' / 'Low T' Construct. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Layton et al., JAMA Internal Medicine2014
Documented rapid rise in testosterone prescribing and that a substantial fraction of new users lacked recent testosterone testing
Vigen et al., JAMA2013
Observational signal of increased adverse cardiovascular events with testosterone therapy (later contested) that helped trigger FDA review
FDA Drug Safety Communication2015
Restricted approved indication to hypogonadism from underlying medical conditions; required cardiovascular warning